Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05757544
Other study ID # 1042-SE-2002
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date April 1, 2023
Est. completion date February 2026

Study information

Verified date May 2024
Source Marinus Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to optimize the dosing regimen and evaluate the preliminary safety and efficacy of Intravenous (IV) ganaxolone as adjuvant therapy for participants with ESE receiving initial IV antiepileptic drug (AED) according to currently practiced standard of care (SOC). The study will be composed of 2 phases: an initial, open-label, dose optimization phase followed by IV ganaxolone versus placebo double-blind phase.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date February 2026
Est. primary completion date February 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Males or females at least 18 years of age at the time of the first IP bolus dose. 2. Has received benzodiazepines before or after arrival to the ED for generalized convulsive seizures lasting more than 5 minutes. 3. Has received the last dose of benzodiazepine more than 5 minutes prior to the first IP bolus initiation. 4. Ongoing or recurrent convulsions, or evidence of electrographic SE on rapid EEG immediately prior to the first IP bolus initiation. 5. The participant has not yet received a second-line IV AED for the treatment of the current episode of SE or the first IP bolus can be initiated within 15 minutes before or 10 minutes after the administration of such IV AED(s). Exclusion Criteria: 1. The participant is intubated or the decision to proceed with intubation has been made. 2. The cause of SE is acute anoxic brain injury, cardiac arrest, acute trauma, hyper- or hypo-glycemia, or eclampsia. 3. The participant is known or suspected to be pregnant. 4. The participant is incarcerated at the time of SE occurrence. 5. Participants who pre-emptively opted out of the study. 6. A known allergy or sensitivity to progesterone or allopregnanolone medications/ supplements. 7. Receiving a concomitant IV product containing Captisol®. 8. Known estimated glomerular filtration rate (eGFR) <30 milliliters per minute (mL/min) and not receiving dialysis (may initiate first IP bolus prior to acute labs). 9. Individual weighing or suspected to weigh <40 kilograms (kg). 10. Hypotension requiring 2 or more vasopressors. 11. An individual who, in the opinion of the investigator has a life expectancy of less than 24 hours. 12. Use of an investigational product for which less than 30 days or 5 half-lives have elapsed from the final product administration. Participation in a non-interventional clinical study does not exclude eligibility. 13. Known or suspected history or evidence of a medical condition that, in the investigator's judgment, would expose participant to an undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
IV Ganaxolone
IV Ganaxolone will be administered.
IV Placebo
IV Placebo will be administered

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Marinus Pharmaceuticals

Outcome

Type Measure Description Time frame Safety issue
Primary Absence of electrographic (rapid electroencephalography [EEG]) evidence of status epilepticus or recurrence of convulsions at 1 hour after the first IP bolus administration without the use of any additional medications with anti-seizure properties At 1 hour
Secondary Percentage of participants with no escalation of care for Status epilepticus (SE) during investigational product (IP) infusion Up to Day 7
Secondary Time to clinical seizure and electrographic SE cessation Up to Day 7
Secondary Percentage of participants with no escalation of care (including re-administration of IP) at any point within 24 hours from the initial IP bolus administration Up to 24 hours
Secondary Percentage of participants with no escalation to IV anesthesia for treatment of seizures during IP infusion Up to Day 7
Secondary Percentage of participants with no escalation to IV anesthesia for treatment of seizures within 24 hours of the initial IP bolus Up to 24 hours
Secondary Time to clinical or electrographic seizure recurrence within 24 hours from the initiation of the first IP bolus Up to 24 hours
See also
  Status Clinical Trial Phase
Recruiting NCT03883516 - Improving Emergency Management of Status Epilepticus N/A
Recruiting NCT03378687 - A Clinical Study of Children With Status Epilepticus in China N/A
Recruiting NCT00362141 - Safety and Tolerability Study of Levetiracetam to Treat Patients With Status Epilepticus Phase 2
Recruiting NCT05140265 - De-identified UNMH EEG Corpus Database Creation With Fully De-identified Clinical Information
Active, not recruiting NCT04391569 - Randomized Therapy In Status Epilepticus Phase 3
Recruiting NCT06017973 - The Role of Imaging in the Diagnosis, Management and Prognosis of Possible Non-convulsive Status Epilepticus N/A
Completed NCT06334796 - Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology Early Phase 1
Recruiting NCT05491590 - Patient-reported Outcome After Status Epilepticus
Recruiting NCT04421846 - Study of Pathophysiology of Status Epilepticus and Dysimmune Encephalitis N/A
Completed NCT02958605 - Smartphone Apps for Pediatric Resuscitation N/A
Completed NCT02239380 - Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan Phase 3
Completed NCT01796574 - Ketogenic Diet for Refractory Status Epilepticus N/A
Completed NCT02381977 - Prevalence of Acute Critical Neurological Disease in Children: a Global Epidemiological Assessment N/A
Completed NCT00004297 - Phase III Randomized Study of Diazepam Vs Lorazepam Vs Placebo for Prehospital Treatment of Status Epilepticus Phase 3
Completed NCT03905798 - LORA-PITA IV General Investigation
Recruiting NCT05591508 - Ketogenic Diet for Status Epilepticus in Children Post Cessation of Convulsive Status Epilepticus N/A
Completed NCT00735527 - Nasal Versus Venous Lorazepam for Control of Acute Seizures in Children Phase 3
Terminated NCT00265616 - Treatment of Refractory Status Epilepticus Phase 3
Recruiting NCT06401707 - PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest Phase 2
Enrolling by invitation NCT06403150 - The Efficacy and Safety of Levetiracetam Versus Fosphenytoin in Convulsive Status Epilepticus Phase 4